Superworth

Teva Pharmaceutical Industries price to sales ratio TEVA

Market value divided by revenue over the last twelve months, since 2018.

Today, Nov 3, 2026
2.9×
8-year median
0.8×
Against its 8-year history
100th
percentile: 0 is its lowest day, 100 its highest
8-year range
0.4× to 2.8×
Peer median
6.7×

Teva Pharmaceutical Industries' price to sales ratio is 2.9× as of Nov 3, 2026.

That is above its 8-year median of 0.8×, higher than on 100% of days in the last 8 years.

Over that time it ranged from 0.4× in Aug 2019 to 2.8× in Oct 2026.

The median for 10 healthcare stocks of a similar size is 6.7×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.7×1.9×2.8×
20252.2×0.9×2.2×
20241.5×0.8×1.5×
20230.8×0.5×0.8×
20220.7×0.5×0.8×
20210.5×0.5×0.8×
20200.6×0.5×0.9×
20190.6×0.4×1.0×
20180.8×0.8×1.2×

Against its peers

Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first, today.

CompanyPrice to sales ratio
TEVATeva Pharmaceutical Industries2.9×
AAgilent Technologies6.7×
HUMHumana0.3×
MDLNMedlinen/m
WATWaters10.0×
IQVIQVIA2.5×
IDXXIDEXX Laboratories11.4×
EWEdwards Lifesciences8.4×
BDXBecton, Dickinson and2.6×
ONCBeOne Medicines6.6×
RPRXRoyalty Pharma15.3×
Peer median6.7×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Teva Pharmaceutical Industries

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.